Nitto Denko Avecia
Milford, MA
Program data pending ClinicalTrials.gov matching
· Last scored 2026-03-15
63.0
Signal Score
✓ FDA Inspections (1)
○ Clinical Trials
○ SEC Filings
✓ Press (1)
Quick Facts: Nitto Denko Avecia
- Signal Score
- 63.0/100 (as of 2026-03-15)
- Quality Compliance
- Assessment pending
- Headquarters
- Milford, MA
- Modalities
- Oligonucleotide, mRNA
- Active CGT Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CGT manufacturing intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA Inspections1 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2024-08-20)
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesOligonucleotide, mRNA
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
68.0
Parent company: Nitto Denko (6988.T)
Financial assessment: 69.0/100
Source: SEC EDGAR, press monitoring
Subsidiary of Nitto Denko
SEC FilingsParent: Nitto Denko
Parent company: Nitto Denko (6988.T)
Financial assessment: 69.0/100
Capacity
58.0
1 CGT manufacturing site: Milford, MA
Modalities: Oligonucleotide, mRNA
Capacity assessment: 58.0/100
Sites: Milford, MA
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
Recent Press1 articles
1 CGT manufacturing site: Milford, MA
Modalities: Oligonucleotide, mRNA
Capacity assessment: 58.0/100
FDA Inspection History
2024-08
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2024-08-20 | Cincinnati, Ohio | Drug Quality Assurance | No | No Action Indicated (NAI) |
Source: FDA Data Dashboard · Retrieved Mar 20, 2026
Recent News 1 articles
Codexis Q4 Earnings Call Highlights - MarketBeat
Codexis Q4 Earnings Call Highlights MarketBeat
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: